ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH AUTHORITY

ADMINISTRATIVE PROCEDURES

Date Issued: 03/20

Page 1

					1 age 1
CHAPTER			CHAPTER	SECTION	SUBJECT
Health/Medical			04	001	0085
SECTION		SUBJECT			
Drugs and Medications Clozaril (Clozap		ine) Clinic			
WRITTEN BY	REVISED BY			AUTHORIZE	D BY
Pat McLellan and Peggy Lawton	Karen Recker, RN CENMe		elissa	Tracey Pingitor	e
	Nicholso	n			

I. APPLICATION:

SCCCMHA Providers & Sub-Contract

Providers
SCCCMHA Board
Direct Operated Programs

Community Agency Programs

Residential Programs
Specialized Foster Care

II. **PURPOSE STATEMENT:**

St. Clair County Community Mental Health Authority (SCCCMHA) shall ensure a coordinated management system regarding the prescribing and monitoring of the medication Clozaril (Clozapine). For all prescribing management and monitoring guidelines for the use of Clozaril also referred to as clozapine from this point forward in this document, refer to Clozapine REMS Program at https://www.clozapinerems.com/CpmgClozapineUI/home.u. Furthermore, St. Clair Community Mental Health Authority (SCCCMHA), shall comply with the Clozapine REMS Program which is an FDAmandated program implemented by the manufacturers of clozapine which is intended to assist Health Care Providers (HCP) ensure the safety of patients on clozapine. Clozapine REMS is a single shared registry with requirements for prescribers, pharmacists, patients and distributors. It shall always be the administrative procedures and directive that when prescribing clozapine, prescriber is to follow the requirements and guidelines set forth in the Clozapine REMS Program.

III. **DEFINITIONS**:

- ANC (Absolute Neutrophil Count): Neutrophils are a type of white blood cell. Clozaril can induce neutropenia, which is a decrease in the absolute neutrophil count and can be life threatening, which is why scheduled lab monitoring is a requirement. The ANC is specified (or it can be referred to as the PMN count, which is the polymorphonuclear count) in the listed results of the differential. It may also be calculated by multiplying the total WBC by the total percentage of neutrophils from the differential.
- Benign Ethnic Neutropenia (BEN): An ethnic-specific condition which results in a normally low baseline neutrophil count. Refer to the Clozaril REMS algorithm for the adjusted acceptable ANC guidelines.

CHAPTER		CHAPTER	SECTION	SUBJECT
Health/Medical		04	001	0085
SECTION Drugs and Medications	SUBJECT Clozaril (Clozap:	ine) Clinic		

- C. <u>Clozaril (Clozapine)</u>: An atypical anti-psychotic used for treatment resistant schizophrenia, and reducing suicidal behaviors in patients with schizophrenia or schizoaffective disorder which typically have not responded to traditional pharmaco-therapeutic agents.
 - D. <u>Clozaril Monitoring Program:</u> The monitoring program that is implemented through designated local laboratories and contractual pharmacies, and conforms to the protocols and standards as established by the Food and Drug Administration (FDA).
- E.D. Clozaril Nurse: A Registered Nurse assigned to monitor and execute a smooth, efficient and safe clinic for individuals receiving Clozaril. All nurses, pharmacists and prescribers must be certified in the REMS Program. To complete this go to https://www.clozapinerems.com/CpmgClozapineUL/home.u.
- F.E. REMS Program (Clozapine Risk Evaluation and Mitigation Strategy): Clozapine can induce neutropenia which is a reduced number of neutrophils and can be life-threatening. The requirements to prescribe, dispense, and receive clozapine are incorporated into a single shared program called the Clozapine Risk Evaluation and Mitigation Sharing Strategy (REMS). A REMS is a strategy to manage known or potential risks associated with a drug or group of drugs, and is required by the FDA for clozapine to ensure that the benefits of the drug outweigh the risk of severe neutropenia. The Clozapine REMS Program replaces the individual clozapine patient registries and the National Non-Rechallenge Master File (MMRMF).
- G.F. WBC (White Blood Cell Count): Total number of white blood cells (leukocytes) in 1 cubic millimeter of peripheral venous blood specimen.

IV. <u>STANDARDS</u>:

INDIVIDUAL SELECTION

- A. Clozapine is an atypical antipsychotic indicated for treatment resistant schizophrenia or schizoaffective disorder, and in reducing suicidal behavior in patients with these diagnoses. Patients must be enrolled in the Clozapine REMS Program by the prescriber or prescribers certified designee.
- B. Individuals being considered for treatment with clozapine, should demonstrate unsatisfactory response to at least 2 typical or atypical anti-psychotic agents at prescribed doses and for a duration of time as determined by the treating psychiatrist, prior to being considered for Clozaril therapy.
- C. Before starting treatment with clozapine, the baseline ANC must be at least 1500/uL for the general population and at least 1000uL for patients diagnosed with BEN (benign ethnic neutropenia).

Formatted: Indent: Left: 0.88", No bullets or numbering

Page 2

CHAPTER Health/Medical		CHAPTER 04	SECTION 001	SUBJECT 0085
SECTION Drugs and Medications	SUBJECT Clozaril (Clozap	ine) Clinic		

D. After initiation of treatment with Clozaril, the ANC counts need to be monitored as per guidelines in the Clozapine REMS which also provide recommendations for Clozapine long-term treatment

V. PROCEDURES:

A. Pre-Clozaril Treatment

Psychiatrist

 Determines individual's appropriateness for Clozaril treatment and orders baseline laboratory test— CBC with differential. ANC must be within the stated ranges as put forth in the Clozaril REMS guidelines.

Psychiatrist/Registered Nurse

Acquires written Informed Consent and-pProvides oral/written educational information related
to Clozaril, by providing access to the video "Is It Time to Consider Clozaril, and by providing
the handout, +"A Guide for patients and Caregivers: What You Need to Know about
Clozapine and Neutropenia". Thiswhich is available to be downloaded from the website.
Nurse or prescribers must register patient into the Clozapine REMS before prescribing and
baseline ANC entered.

Contractual Pharmacy

- Enters electronically theenters individual beginning Clozaril into the Clozapine REMS
 Program and receives Predispense Authorization (PDA) before Clozapine can be dispensed. A
 PDA is an electronic code that indicates the Clozapine REMS program has verified:
 - a. The prescriber is certified in the Clozapine REMS Program.
 - b. The pharmacy is certified in the Clozapine REMS Program.
 - c. The patient is enrolled in the Clozapine REMS Program.
 - d. The ANC is current (<u>results are within 7 days of dispensing</u>) and acceptable according to the patient's monitoring schedule, or the prescriber has authorized the continuation of Clozapine treatment.

Clozaril Nurse

4. Reviews pre-Clozaril baseline CBC/Diff results and links to prescriber.

CHAPTER		CHAPTER	SECTION	SUBJECT
Health/Medical		04	001	0085
SECTION Drugs and Medications	SUBJECT Clozaril (Clozapi	ine) Clinic		

- 5. Records the results of the baseline WBC and ANC count on the individual's WBC and ANC History (From #110) in the Clozaril nurse reference book. Enters lab data from each draw and within the required guideline frequencies in the Clozaril Registry. Sends laboratory report to the individual's Pharmacy for dispense. SCCCMHA utilizes Genoa Pharmacy or Kroger Pharmacy if the individuals insurance does not allow Genoa to fill Clozaril.
- Sends the following information to the contractual pharmacy at least 24 hours before Clozaril treatment is to start:
 - Ensure that contractual pharmacy has received original physician's order in written form or by electronic script.
 - b. Lab results completed within 7 days of dispensing.
 - c. Copy of insurance/Medicaid card or other approved payment method.

Psychiatrist/Nurse Practitioner

7. Prescribes Clozaril dosage titration. Clozaril titration schedule (Exhibit \underline{AC}) is available as guideline. Physician order is maintained in electronic file.

Clozaril Nurse

8. Ensures individuals and assigned case managers are aware of site, time, and day of the Clozaril Clinic.

B. Active Clozaril Treatment

Psychiatrist

 Reviews the medication at least every ninety (90) days or as clinically indicated. Prescribes Clozaril (Clozapine) with refills.

Clozaril Nurse

- 2. Maintains Clozaril order-is maintained in the electronic file.
- Assesses individual during Clozaril clinic as to tolerance and side effects associated with Clozaril.

CHAPTER		CHAPTER	SECTION	SUBJECT
Health/Medical		04	001	0085
SECTION Drugs and Medications	SUBJECT Clozaril (Clozap	ine) Clinic		

4. Reviews results of CBC (in accordance with Section IV. D.) and records WBC and ANC on individual's Clozaril record (form #110). Inputs results into Clozaril registry with each scheduled blood draw.

scheduled blood draw.

- 5. Maintains electronic lab results in the individual's EHR.
- Informs psychiatrist and individual's assigned treatment staff of abnormal laboratory results or any pertinent clinical information.
- Discusses with provider/individual if emergency supply is needed; and obtains order from psychiatrist appropriate.
- Completes all the appropriate case record documentation. Completes a Progress/Contact Note for face-to-face contacts.

Home Provider

9. If Clozaril treatment is stopped for two (2) days or more, Ceontacts the prescribing psychiatrist/nurse practitioner for dosing instructions, if Clozaril treatment is stopped for two (2) days or more.

Case Manager/Home Provider

10. Notifies Clozaril Nurse one (1) week in advance of individual's vacation plans if vacation is outside of St. Clair County and longer than two (2) weeks.

C. Individuals Placed In St. Clair County CMH During Clozaril Treatment

CMH Institutional Liaison, Placement Coordinator, or Outpatient Intake Clinician

- 1. Notifies Clozaril nurse at least seven (7) days prior to placement to ensure a smooth transition for continued Clozaril therapy.
- 2. Provides the Clozaril nurse with the following information:
 - a. Social Security number.
 - b. Copy of insurance or Medicaid card.
 - c. Current Clozaril dosage with copy of current physicians order.

Formatted: Font: Bold

CHAPTER		CHAPTER	SECTION	SUBJECT
Health/Medical		04	001	0085
SECTION Drugs and Medications	SUBJECT Clozaril (Clozapi	ine) Clinic		

- d. ANC counts from last four (4) blood tests.
- e. List of other medications individual is currently receiving.
- 3. Requests CBC with Differential to be drawn on the day of discharge from previous Clozaril monitoring program (i.e., institution, OP labs, etc.).
- 4. Ensures laboratory results are faxed immediately to the Clozaril nurse.
- 5. Ensures individual is placed into CMH system with a seven (7) day supply of Clozaril.

Clinician/Case Manager

Ensures individual is seen by CMH contractual physician/psychiatrist within seven (7) days of placement or transfer into CMH system.

Clozaril Nurse

7. Follows procedures as outlined in Section (V.B) ACTIVE CLOZARIL TREATMENT for the remaining steps.

D. Termination Of Clozaril Treatment

Psychiatrist

1. Writes the order to discontinue Clozaril in the EHR.

Case Manager/Registered Nurse

2. Receives notification of intent to discontinue Clozaril. Notifies caregiver, if applicable, that the medication is being discontinued.

Clozaril Nurse

- 3. Documents discontinuation of Clozaril on individual's Nursing Progress/Contact Note.
- Directs individual/caregiver that a post CBC/Diff is required to assure individual is not
 experiencing post Clozaril neutropenia. Once lab results are available they are entered into the
 Clozaril Registry.
- Ensures that the contractual pharmacy has received electronic script for discontinuation of Clozaril.

Page 7

CHAPTER	· ·	CHAPTER	SECTION	SUBJECT
Health/Medical		04	001	0085
SECTION Drugs and Medications	SUBJECT Clozaril (Clozap	ine) Clinic		

VI. <u>REFERENCES</u>:

A. Clozaril REMS

https://www.clozapinerems.com/CpmgClozapineUI/home.u

B. Clozaril & Risk of Neutropenia: A Guide for Health Care Providers

https://www.clozapinerems.com/CpmgClozapineUI/rems/pdf/resources/Clozapine_REMS_A_Guid

e_for_Healthcare_Providers.pdf

VII. EXHIBITS:

- A. Clozaril (Clozapine) Titration Schedule
- B. Clozapine REMS Guidelines

VIII. REVISION HISTORY:

Dates issued 09/90; 12/91; 07/94; 09/97; 08/05; 08/07; 08/09; 08/11; 11/12; 11/13; 11/14; 11/15; 11/16; 01/18; 01/19.

Formatted: No bullets or numbering

Formatted: No bullets or numbering, Tab stops: 0.81", Left + Not at 0.88"

Formatted: Indent: Left: -0.69", Hanging: 1.5", No bullets or numbering, Tab stops: 0.81", Left + Not at 0.88"

EXHIBIT A

CLOZARIL (CLOZAPINE) TITRATION SCHEDULE

CONSUMER NAME		CASE NO	DATE
B.P. Sitting	B.P. Standing	Pulse	Resp
	DOSAG	GE FOR FIRST WEEK	
DAY 1 (DAY & DATE)	TAKE ONE-HALF OF A	25 MG TABLET AT CLO	ZARIL CLINIC APPOINTMENT.
DAY 2 (DAY & DATE)	TAKE ONE-HALF OF A 2	25 MG TABLET TWICE A	A DAY (MORNING & BEDTIME).
DAY 3 (DAY & DATE)	TAKE ONE - 25 MG TAB	BLET TWICE A DAY (MC	DRNING & BEDTIME).
DAY 4 (DAY & DATE) BE	TAKE ONE- 25 MG TABI DTIME).	LET THREE TIMES A DA	AY (MORNING, AFTERNOON &
DAY 5 (DAY & DATE) TA	TAKE ONE - 25 MG TAB KE TWO – 25 MG TABLETS		AND ONE IN THE AFTERNOON.
DAY 6 (DAY & DATE) TA	TAKE ONE - 25 MG TAB KE THREE – 25 MG TABLE		AND ONE IN THE AFTERNOON.
DAY 7(DAY & DATE) TAI	TAKE ONE - 25 MG TAB KE FOUR – 25 MG TABLET	LET IN THE MORNING S AT BEDTIME.	AND ONE IN THE AFTERNOON.
	DOSAGE	FOR SECOND WEEK	
DAY 8 (DAY & DATE)	TAKE ONE - 25 MG TAB TAKE TWO - 25 MG TAI TAKE ONE - 100 MG TA	BLETS IN THE AFTERNO	OON.
DAY 9 (DAY & DATE)	TAKE ONE - 25 MG TAB TAKE THREE - 25 MG T TAKE ONE - 100 MG TA	LET IN THE MORNING. ABLETS IN THE AFTER BLET AT BEDTIME.	NOON.
DAY 10(DAY & DATE)	TAKE ONE - 25 MG TAB TAKE ONE - 100 MG TA TAKE ONE - 100 MG TA	BLET IN THE AFTERNO	OON.
DAY 11 (DAY & DATE)	TAKE TWO - 25 MG TAB TAKE ONE - 100 MG TA TAKE ONE - 100 MG TA	BLET IN THE AFTERNO). ION.
DAY 12 (DAY & DATE)	TAKE THREE - 25 MG TA TAKE ONE - 100 MG TA TAKE ONE - 100 MG TA	BLET IN THE AFTERNO	NG. ION.
DAY 13 (DAY & DATE) BEI	TAKE ONE - 100 MG TAE DTIME).	BLET THREE TIMES A D	AY (MORNING, AFTERNOON &
DAY 14 (DAY & DATE) BED	_ TAKE ONE - 100 MG TAE DTIME).	BLET THREE TIMES A D	AY (MORNING, AFTERNOON &

EXHIBIT B

Clozapine and the Risk of Neutropenia: A Guide for Healthcare Providers





Before starting treatment with clozapine, the baseline ANC must be:

- at least 1500/ μL for the general population at least 1000/ μL for patients diagnosed with BEN

During treatment, monitor ANC regularly as described in Table 1 below.

Table 1: Recommended Monitoring Frequency and Clinical Decisions by ANC Level

ANC Level	Treatment Recommendation	ANC Monitoring
Normal Range for a New Patient GENERAL POPULATION • ANC ≥ 1500 J.L.	Initiate treatment If treatment interrupted:	Weekly from initiation to six months Every two weeks from 6 to 12 months Moranly after 12 months
BEN POPULATION • ANC ≥ 1000/y£. • Obtain at least two baseline ANC levels before initiating treatment	Discontinuation for reasons other than neutropenia	Bee Section 2.4 of the full Prescribing Information
MEd Neutropenia (1000 - 1499:µL)*	GENERAL POPULATION - Continue treatment	GENERAL POPULATION Three times weekly until ANC a 1500/μL Once ANG a 1500/μL return to patient's last 'Normal Range' ANG monitoring internal.
	BEN POPULATION • Main neutropenia is normal range for BEN population, constitue treatment • Oebian at least the baseline ANO levels before initiating treatment • If treatment interrupted • 30 days, continue monitoring as before • 30 days, continue monitoring as before • 30 days, monitor as if new patient • Occontinuation for reasons other than neutropenia	BEN POPULATION Weekly from initiation to six months Every bus weeks from 6 to 12 months Monthly after 12 months One Decision 2.4 of the full Prescribing information
Moderate Neutropenia (500 - 993\/L.)*	OENERAL POPULATION Recommend hematology consultation Interrupt treatment for suspected disapplie-induced neuropeans Resume treatment once ANO normalizes to a: 1000/µL	GENERAL POPULATION Obly until ANO a 1000 jul, then Three times weetly until ANO a 1500 jul Once ANO of 1500 jul, check ANO weetly for 4 weets, then return to patient's last "Normal Range" ANO monitorion miteral"
	BEN POPULATION Recommend hematology consultation Continue treatment	BEN POPULATION Time times weekly until ANG a 1000/ul. or a patient's known baseline. Once ANG a 1000/ul. or patient's known baseline, check ANG weekly for a weekly, then return to patient's last Ynomia BEN Ranger ANG monitoring intersi".
Bevere Neutropenta (< EDB/pL)*	OENERAL POPULATION Recommend hematicopy consultation Interrupt treatment for suspected clossapine-induced neutroperia Do not rechallenge unless prescriber determines benefits outsetyln treatment.	OENERAL POPULATION - Daily until AND & 1000JuL - Three bines weekly until AND & 1500JuL - If patient rechallenged, resume treatment as a new patient under "Normal Range" monitoring once AND & 1500JuL
	BEN POPULATION Recommend hematology consultation Internut treatment for suspected clozapine-induced neuropenia Do not rechallenge unless prescriber determines benefits outwelpf risks	BEN FORULATION Daily until ANO 2 500/uL Three times weekly until ANO a patient's established baseline If patient rechallenged, resume treatment as a new patient under "formal BEN Range" monitoring once ANO 21000/uL o at patient's baseline

Reference ID: 4376730

Table 1: Recommended Monitoring Frequency and Clinical Decisions by ANC Level

ANC Level	Treatment Recommendation	ANC Monitoring
Normal Rango for a New Patient GENERAL POPULATION • ANC ≥ 1500/µL BEN POPULATION	Initiate treatment If treatment interrupted: < 30 days, continue monitoring as before ≥ 30 days, monitor as if new patient	Weekly from Initiation to six months Every 2 weeks from 6 to 12 months Monthly after 12 months
ANC ≥ 1000/μL Obtain at least two baseline ANC levels before initiating treatment.	Discontinuation for reasons other than neutropenia	See Section 2.4 of the full Prescribing Information
Mild Neutropenia (1000 - 1499/µL)'	GENERAL POPULATION • Continue treatment	GENERAL POPULATION Three times weekly until ANC ≥ 1500/µL Once ANC ≥ 1500/µL return to patient's last 'Normal Range' ANC monitoring interval**
	BEN POPULATION • Mild Neutropenia is normal range for BEN population, continue treatment • Obtain at least two baseline ANC levels before initialing treatment • If reatment interrupted • <30 days, continue monitoring as before • ≥ 30 days, monitor as if new patient	BEN POPULATION • Weekly from initiation to six months • Every 2 weeks from 6 to 12 months • Monthly after 12 months
	Discontinuation for reasons other than neutropenia	See Section 2.4 of the full Prescribing Information
Moderate Neutropenia (600 - 998(µL)*	GENERAL POPULATION Recommend hematology consultation Interrupt treatment for suspected clozapine induced neutropenia Resume treatment once ANC normalizes to ≥ 1000/µL	GENERAL POPULATION Daily until ANC ≥ 1000/pt., then Three times weekly until ANC ≥ 1500/pt. Onco ANC ≥ 1500/pt. check ANC weekly for 4 weeks, then return to patient's last "Normal Range" ANC monitoring interval**
	BEN POPULATION Recommend hematology consultation Continue treatment	BENPOPULATION Three times weekly until ANC ≥ 1000/µL or ≥ patient's known baseline Once ANC ≥ 1000/µL or patient's known baseline, check ANC weekly for 4 weeks, then return to patient's last "Normal BEN Range" ANC monitoring interval.**
Severe Neutropenia (< 500/µL)*	GENERAL POPULATION Recommend hematology consultation Interrupt treatment for suspected clozapine induced neutropenia Do not rechallenge unless prescriber determines benefits outwelgh risks	GENERAL POPULATION Daily until ANC ≥ 1000/µL Three times weekly until ANC ≥ 1500/µL If patient rechallenged, resume treatment as a new patient under "Normal Range" monitoring once ANC ≥1500/µL
	BEN POPULATION Recommend hemalology consultation Interrupt treatment for suspected clozaping Induced neutropenia On not rechallenge unless prescriber determines benefits outweigh risks	BEN POPULATION Delify until ANC ≥ 500/µL Three times weekly until ANC ≥ patients established baseline If patient rechallenged, resume treatment as a new patient under Normal Range* monitoring once ANC ≥ 1000/µL or at patient's baseline

^{*} Confirm all initial reports of ANC less than 1500/µL (ANC < 1000/µL for BEN patients) with a repeat ANC measurement within 24 hours
** If clinically appropriate

September 2015

6